Тромбозы и тромбоэмболии в онкологии. Современный взгляд на проблему

Автор: Сомонова О.В., Маджуга А.В., Елизарова А.Л.

Журнал: Злокачественные опухоли @malignanttumors

Статья в выпуске: 3 (10), 2014 года.

Бесплатный доступ

Для больных злокачественными новообразованиями характерен высокий риск развития тромботических осложнений, которые осложняют противоопухолевое лечение и ухудшают выживаемость онкологических больных. Основную роль в патогенезе тромботических осложнений у больных злокачественными новообразованиями играют изменения в системе гемостаза, вызываемые как самой опухолью, так и методами лечения. Низкомолекулярные гепарины являются основой специфической профилактики тромбоэмболических осложнений у онкологических больных. Применение низкомолекулярных гепаринов до и после операции и на фоне химиотерапии уменьшает активацию внутрисосудистого свертывания крови, снижает частоту венозных тромбозов и предотвращает смертельные ТЭЛА, что расширяет возможности противоопухолевого лечения и повышает качество жизни онкологических больных.

Еще

Онкологические больные, тромботические осложнения, низкомолекулярные гепарины

Короткий адрес: https://sciup.org/14045493

IDR: 14045493

Список литературы Тромбозы и тромбоэмболии в онкологии. Современный взгляд на проблему

Agnelli G., Verso M. Management of venous thromboembolism in patients with cancer.//Journal of thrombosis and haemostasis.-2011.-V.9 (Suppl 1). -P.316-324
Levine M.N., Rickles F., Kakkar A. K. Thrombosis in cancer patients//American Society of Clinical Oncology, 38 Annual Meeting, Orlando -2002.-May 18-21.-P.57-60
Trousseau A. Phlegmasia Alba Dolens. Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris//London: New Sydenham Society.-1872.-P.281-295
Geerts W.H., Pineo G. F., Heit J. A. et al. Prevention of venous thromboembolism //. The Seventh ACCR Conference on Antithrombotic and Thrombolytic Therapy// Chest.- 2004.- V.126 (Suppl).- P.338S-400S
Kakkar A.K., Haas S., Walsh D. et al. Prevention of perioperative venous thromboembolism: outcome after cancer and non-cancer surgery (abstract)//Thromb. Haemost.-2001.-V.86 (suppl).-P.0c1732
Hillen H. F. Thrombosis in cancer patients//ESMO, Annuаl. of oncology.-2000.-V.11 (suppl.3).-P.273-276
Hirsh J., Anand S. S., Halperin J. L., Fuster V. Guide to Anticoagulant therapy: Heparin. A Statement for healthcare Professionals from the American Heart Association//Curculation.-2001.-V.105.-P.2994-3018
Cohen A.T., Nandini B., Wills J. O. et al. VTE prophylaxis for the medical patients: where do we stand? -A focus on cancer patients.//Thromb. Res.-2010.-V.125 (Suppl 2).-P.S21-S29
Amin C., Mackman N., Key N. C. Microparticles and cancer.//Pathophysiol. Haemost.Thromb.-2008.-V.36.-P.177-83
Simanek R., Vormittag R., Alguel G.et al. A high platelet count independently predicts venous thromboembolism in cancer patients//J.Thromb. Haemost.-2007.-V.5 (suppl.2).-P.493-497
Chand H.S., Ness.A., Kisiel W. Identification of a novel human tissue factor splice variant that is upregulated in tumor cells.//Int.J.Cancer-2006.-Apr.1.-V.118.-P.1713-20
Petralia G.A., Lemoine N. R., Kakkar A. K. Mechanisms of disease: the impact of antithrombotic therapy in cancer patients.//Nat.Clin.Pract.Oncol.-2005.-V.2.-P.356-63
Ten C.H., Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis//Pathophysiology. Haemost. Thromb.-2007.-V.36.-P.122-`130
Magnus N., D’Asti E., Meehan B., et al. Oncogenes and the coagulation system -forses that modulate dormant and aggressive states in cancer//Thrombosis Research.-2014.-V.133 (Suppl.2).-P.S1-S9
Сомонова О.В., Маджуга А. В., Елизарова А. Л., Зубрихина Г. Н. Тромботические осложнения и их профилактика в онкологии//Новые возможности лекарственного лечения онкологических больных. Материалы школы по онкологии (химиотерапия опухолей). XIV Российский Национальный конгресс «Человек и лекарство».-М.-2007.-С.135-137
Mandala M., Labianca R. Venous thromboembolism (VTE) in cancer patients. ESMO Clinical Recommendations for prevention and management//Thrombosis Research.-2010.-V.125 (Suppl 2).-P.S117-S119
Agnelii G., Bergqvist D., Cohen A. et al. Randomized double-blind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra) and preoperative dalteparin in the prevention of venous thromboembolism after high risk abdominal surgery: the PEGASUS Study (abstract)//Blood.-2003.-V.102.-P.15-P18
Connoly G.C., Khorana A.A Emerging risk stratification approaches to cancer -associated thrombosis: risk factors, biomarkers and a risk score.//Thrombosis Research.-2010.-V.125 (Suppl.2).-P.S1-S8
Bloom J. W., Vanderschoot J. P., Oostindier M. J. et al. Incidence of venous thrombosis in a large cohort of 66329 cancer patients: results of a record linkage study.//J.Thromb. Haemost.-2006.-V.4.-P.529-35
Otten H. M., Mathijssen J., Ten C. H. et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon.//Arch. Inter. Med.-2004.-V.164.-P190-4
Agnelii G., Verso M. Thromboprophylaxis during chemotherapy in patients with advanced cancer//Thrombosis Research.-2010.-V.125 (Suppl.2). -P.S17-S20
Levine M. N. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy//Thromb. Haemost.-1997.-78.-133-6
Kroger K., Weiland D., Ose C. et.al. Risk factors for venous thromboembolic events in cancer patients//Ann. Oncol.-2006.-17.-297-303
Gugliotta L., Mazzucconi M., Leone G. et. al. Incidence of thrombotic complication in adult patients with acute lymphoblastic leucemia receiving L-asparaginase during induction therapy//Eur. J. Haematol.-1992.-49.-63-66
Scappaticci F., Fehrenbacher L., Cartwright T. et.al. Surgical wound healing complictions in metastatic colorectal cancer patients treated with bevacizumab//J. Surg, Oncol.-2005.-91.-173-80
Choueiri t., T., Schutz F., Je Y. et al. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials//J. Clin.Oncol.-2010.-28.-2280-5
Cavo M., Zamagni E., Cellini C. et al. Deep -vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy//Blood.-2002.-100.-2272-3
Khorana A., McCrae K. Risk stratification strategies for cancer associated thrombosis: an update//Thromb. Res.-2014.-V.133 (Suppl.2).-P.S35-S38
Nallury S., Chu D., Keresztes R. et al. Risk of venous thromboembolism with the angiogeesis ingibitor bevacizumab in cancer patients: a metaanalysis.//J. Amer.Med.Assic.-2008.-300.-2277-85
Khorana A., Kuderer N., Culakova E. et al. Development and validation of a predictive model for chemotherapy-associated thrombosis//Blood.-2008.-111.-4902-7
Bohlius J., Schmidin K., Brillant C. et al. Erythropoetin or darbepoetin for patients with csncer-metaanalysis based on individual patients data. Cochrane Database Syst. Rev.-2009.-3.-CD007303
Cohen A. T., Nandini B., Wills J. O. et al. VTE prophylaxis for the medical patients: where do we stand?-A focus on cancer patients.//Thrombosis Research.-2010.-V.125 (Suppl 2).-P.S21-S29
Becker R. C., Fintel D. J., Green D. Antithrombotic therapy.-2th ed. Americal publishing company.-2002.-352 P
Lee Y., Carrier M. Treatment of cancer-associated thrombosis: perspectives on the use of novel oral anticoagulants//Thrombosis Research.-2014.-V.133 (Suppl.2).-S 167-171
Lee A. Y. The roles of anticoagulants in patients with cancer//Thromb Res.-2010.-V.125 (Suppl.2). -P.S8-S11
Verso M., Agnelii G. New strategies of VTE prevention in cancer patients//Thrombosis Research.-2014.-V.133 (Suppl.2).-S 128-S 132
Agnelii G., Gussoni G., Bianchini C. et. al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomized, placebo-controlled, double-blind study//Lancet.-2009.-10.-943-9
Kuderer N., Lyman G. Guidelines for treatment and prevention of venous thromboembolism among patients with cancer // // Thrombosis Research.-2014.- V.133 (Suppl.2).- S 122-S127

Еще

Статья научная